This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Paul Royalty invests $42mm in Guilford, gets royalty rights
14 Jul 2004
In a deal that will help Guilford Pharmaceuticals fund its acquisition of the cardiovascular drug Aggrastat from Merck & Co., Paul Royalty Funds (PRF)--a unit of Paul Capital Partners set up to acquire royalty and revenue interests of life sciences companies--invested $42mm in the company in exchange for royalties from Guilford's sales of Aggrastat and its brain cancer drug Gliadel.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?